Comparison Overview
ICON Geneesmiddelenonderzoek
ICON Geneesmiddelenonderzoek
Van Swietenlaan 6, Groningen, Nederland, NL, 9728 NZ
Last Update: 08/11/2025
ICON is wereldleider op het gebied van geneesmiddelenonderzoek. In opdracht van farmaceutische bedrijven doen we onafhankelijk onderzoek naar de werking van innovatieve, nieuwe of verbeterde geneesmiddelen bij mensen. In Nederland verrichten we met name klinisch en bioa...
Parexel
541 Church at North Hills St, 1000, Raleigh, North Carolina, US, 27609
Last Update: 03/04/2026
Parexel is a leading global clinical research organization (CRO) providing insights-driven Clinical and Consulting solutions to the world’s life sciences industry. Leveraging deep local knowledge and a global breadth of clinical, regulatory and therapeutic expertise, ou...
Compliance Ranges Comparison
ICON Geneesmiddelenonderzoek
Parexel
Benchmark & Cyber Underwriting Signals
Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)
No incidents recorded for ICON Geneesmiddelenonderzoek in 2026.
Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)
No incidents recorded for Parexel in 2026.
Incident History - ICON Geneesmiddelenonderzoek (X = Date, Y = Severity)
ICON Geneesmiddelenonderzoek cyber incidents detection timeline including parent company and subsidiaries.
Incident History - Parexel (X = Date, Y = Severity)
Parexel cyber incidents detection timeline including parent company and subsidiaries.
Notable Incidents
ICON Geneesmiddelenonderzoek
Parexel
FAQ
Latest Global CVEs
Pronetiqs IntraVUE versions 3.2.1a14 and prior have an inadequate encryption strength vulnerability which could allow an attacker to steal admin credentials via weak hash or a pass-the-hash attack.
Pronetiqs IntraVUE versions 3.2.1a14 and prior have an exposure of sensitive system information to an unauthorized control sphere vulnerability which could allow for asset discovery by unauthenticated users.
Pronetiqs IntraVUE versions 3.2.1a14 and prior have an unintended proxy or intermediary vulnerability which could allow an attacker to use an active proxy, which would bypass OT segmentation.
Pronetiqs IntraVUE Versions 3.2.1a14 and prior have a plaintext storage of a password vulnerability that could expose cleartext credentials through the API.
Pronetiqs IntraVUE versions 3.2.1a14 and prior have an exposure of sensitive system information to an unauthorized control sphere vulnerability which could expose the underlying host/share filesystem.